These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31161973)

  • 1. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
    Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M
    J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes.
    Tay KJ; Cheng CWS; Lau WKO; Khoo J; Thng CH; Kwek JW
    Radiology; 2017 Nov; 285(2):620-628. PubMed ID: 28654336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
    J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study.
    Valerio M; Shah TT; Shah P; Mccartan N; Emberton M; Arya M; Ahmed HU
    Urol Oncol; 2017 Apr; 35(4):150.e1-150.e7. PubMed ID: 27955940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
    Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
    Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
    Ghai S; Finelli A; Corr K; Chan R; Jokhu S; Li X; McCluskey S; Konukhova A; Hlasny E; van der Kwast TH; Incze PF; Zlotta AR; Hamilton RJ; Haider MA; Kucharczyk W; Perlis N
    Radiology; 2021 Mar; 298(3):695-703. PubMed ID: 33529137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
    von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
    Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
    Eggener SE; Yousuf A; Watson S; Wang S; Oto A
    J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
    Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
    Miñana López B; Andrés Boville G; Barbas Bernardos G; Ancizu Marckert X; Torres Roca M; Labairu Huerta L; Villacampa Aubá F; Ramón de Fata Chillón F; Sanz Ortega J; Abengózar Muela M; Gallardo Madueño G; Benito Boíllos A; Alcázar Peral A; Díez-Caballero Alonso F
    J Urol; 2023 Jan; 209(1):261-270. PubMed ID: 36073928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.